Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE versus DIATRIZOATE 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE versus DIATRIZOATE 60.
DIATRIZOATE MEGLUMINE vs DIATRIZOATE-60
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Diatrizoate meglumine is an ionic, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, thereby enhancing radiographic imaging. It does not exert pharmacological effects via receptor interaction but functions by attenuating X-ray beams, providing contrast between vascular structures and surrounding tissues.
Diatrizoate is an ionic, monomeric, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, enhancing radiographic imaging by attenuating X-ray beams. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
Intravascular administration for cerebral angiography, peripheral angiography, coronary arteriography, left ventriculography, aortography, urography, and contrast enhancement for computed tomography (CT)Oral or rectal administration for gastrointestinal tract opacification
Radiographic contrast agent for angiography, urography, computed tomography (CT), and other imaging proceduresOff-label: direct injection for fistulography, arthrography, and hysterosalpingography
Intravenous: 1-2 mL/kg (305-610 mg I/kg) of 60% or 76% solution for urography; 40-60 mL of 50% solution for retrograde cystourethrography. Oral: 200-600 mL of 4.8% suspension for GI contrast.
1-2 mL/kg IV bolus up to 150 mL total for contrast-enhanced CT; repeat doses may be given based on imaging needs.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function (CLcr >90 mL/min). Half-life is significantly prolonged in renal impairment (up to 20-40 hours in anuria), necessitating dose adjustment and caution.
Terminal half-life approximately 1-2 hours in patients with normal renal function. Prolonged in renal impairment (up to 20-30 hours in anuria).
Diatrizoate meglumine is not metabolized; it is eliminated unchanged by glomerular filtration via the kidneys.
Not metabolized; excreted unchanged by the kidneys via glomerular filtration.
Primarily renal excretion via glomerular filtration; >95% of the administered dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary elimination.
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Negligible biliary or fecal elimination.
Negligible protein binding (<5%); binding to albumin is minimal.
Very low; less than 5% bound, primarily to albumin.
Approximately 0.2-0.3 L/kg; distributes primarily in extracellular fluid. Does not significantly cross the blood-brain barrier in intact brain.
Approximately 0.2-0.3 L/kg, confined to extracellular fluid; no significant tissue penetration.
Oral: approximately 0% (not absorbed systemically due to high polarity and low lipophilicity); Intravenous: 100% for direct vascular administration.
Bioavailability is 100% for intravenous and intra-arterial routes; oral bioavailability near 0% (not absorbed).
GFR <30 mL/min: Consider alternative; reduce dose or extend interval. GFR 30-60 mL/min: Caution with reduced dose. No specific dose recommendations; risk of nephrotoxicity.
eGFR >60 mL/min: no adjustment. eGFR 30-60: reduce dose by 50% or use alternative if possible. eGFR <30: avoid use; if essential, use minimum dose (0.5 mL/kg) with pre-hydration and N-acetylcysteine.
No specific dose adjustments; severe hepatic impairment may increase nephrotoxicity risk; use with caution.
No specific dose adjustment for Child-Pugh class; use cautiously in severe hepatic impairment due to risk of nephrotoxicity.
Intravenous urography: 1-2 mL/kg (305-610 mg I/kg) of 60 or 76% solution. Oral GI: <5 years: 60-90 mL of 4.8% suspension; 5-10 years: 150 mL; >10 years: 200-300 mL.
0.5-2 mL/kg IV based on imaging protocol; maximum 150 mL. Adjust for weight: infants: 1-2 mL/kg, children: 1-1.5 mL/kg.
Use lowest effective dose; monitor renal function; increased risk of nephrotoxicity and dehydration; ensure adequate hydration.
Lower initial doses (0.5-1 mL/kg) with careful monitoring of renal function; avoid in eGFR <30 mL/min.
None
Not recommended for intrathecal use; severe neurological complications including seizures, paralysis, and death can occur if administered into the subarachnoid space.
Risk of serious hypersensitivity/anaphylactoid reactions, including fatal cardiovascular and respiratory events; pre-existing renal impairment can lead to contrast-induced nephropathy; caution in patients with sickle cell disease, multiple myeloma, or pheochromocytoma; ensure adequate hydration before administration.
["Risk of acute kidney injury (AKI) in patients with pre-existing renal impairment, diabetes, or dehydration","Anaphylactoid reactions, including hypotension, bronchospasm, and angioedema","Contrast-induced nephropathy (CIN)","Hypersensitivity reactions"]
Absolute: Known hypersensitivity to diatrizoate meglumine or any component, anuria. Relative: History of severe allergic reactions to iodinated contrast agents, advanced renal disease, severe heart failure, hyperthyroidism.
["Known hypersensitivity to diatrizoate or any component","Intrathecal administration (absolute)","Severe renal impairment (relative, use with caution)"]
Data Pending Review
Data Pending Review
No specific food interactions. Maintain adequate hydration; avoid alcohol and caffeinated beverages pre-procedure as they may contribute to dehydration.
No specific food interactions are known. However, patients should maintain adequate hydration with clear fluids before and after contrast administration. Fasting for blood tests may be required prior to the procedure, but this is not a drug-food interaction per se.
Diatrizoate meglumine, an ionic iodinated contrast agent, is not associated with teratogenicity in humans at diagnostic doses. Animal studies have not shown fetal harm. However, theoretical risk of fetal hypothyroidism exists if large doses are administered near term due to free iodide release. Use in pregnancy only if clearly needed.
Diatrizoate is an iodinated contrast agent. There is no evidence of teratogenicity in humans based on limited data; however, as a precaution, avoid use in the first trimester when organogenesis occurs. Inadvertent exposure during pregnancy has not been associated with an increased risk of major birth defects. Use only if clearly needed and risk-benefit justifies exposure.
Diatrizoate meglumine is excreted into breast milk in small amounts. Milk to plasma ratio is approximately 0.5. Absorption from infant gastrointestinal tract is minimal. Clinical guidance: breastfeeding may be continued without interruption after standard diagnostic doses. No adverse effects in nursing infants reported.
Diatrizoate is excreted into breast milk in very low quantities (<0.01% of maternal dose). The M/P ratio is not well defined but is low. The American College of Radiology suggests no special precautions are needed, and breastfeeding can be continued normally after contrast exposure.
No dose adjustment necessary for pregnancy based on pharmacokinetic changes. Pregnancy-induced increases in plasma volume and GFR may slightly alter distribution, but standard diagnostic doses remain effective and safe. Use lowest necessary dose to minimize iodine exposure.
No specific dose adjustments are recommended for pregnancy, but the lowest possible dose should be used to achieve diagnostic imaging. Standard adult dosing applies; however, consider the altered volume of distribution and increased renal clearance in pregnancy, which may affect contrast elimination but not require dose modification.
Category C
Category C
Diatrizoate meglumine is a high-osmolality ionic contrast agent; ensure adequate hydration before and after administration to reduce nephrotoxicity. Premedicate with corticosteroids and antihistamines for patients with prior contrast reaction. Contraindicated in myelography due to potential neurotoxicity. Monitor for delayed hypersensitivity reactions. Use with caution in patients with renal impairment (eGFR <30), multiple myeloma, or pheochromocytoma.
Diatrizoate-60 (Hypaque-60) is a high-osmolar ionic monomer contrast agent used for angiocardiography, excretory urography, and CT enhancement. Pre-hydration with IV fluids reduces risk of contrast-induced nephropathy (CIN) especially in patients with CKD, diabetes, or age >70. Assess renal function (eGFR) prior to administration; consider N-acetylcysteine or sodium bicarbonate protocol in high-risk patients. Risk of delayed hypersensitivity reaction (e.g., rash, fever) up to 72 hours post-injection, especially in patients with prior contrast allergy. Have emergency equipment available for anaphylaxis. In patients with multiple myeloma, dehydration increases risk of renal failure; ensure adequate hydration. Intrathecal administration is contraindicated (use low-osmolar nonionic agents).
Drink plenty of fluids before and after the procedure to flush the contrast from your kidneys.Inform your doctor if you have a history of allergies, asthma, or previous contrast reactions.You may experience a warm sensation or metallic taste during injection; this is normal.Report any hives, difficulty breathing, or swelling after the procedure immediately.If you have diabetes, discuss potential risks of metformin use around the time of the procedure.
You may experience a warm sensation, metallic taste, or flushing during the injection; this is temporary.Drink plenty of water before and after the procedure to help protect your kidneys unless instructed otherwise by your doctor.Notify your doctor immediately if you develop hives, itching, difficulty breathing, or swelling after the procedure.Inform your healthcare providers if you have a history of allergic reactions to contrast dye, asthma, or kidney disease.If you are diabetic and taking metformin, your doctor may ask you to stop it temporarily to prevent a rare complication called lactic acidosis.Mild side effects like nausea or headache may occur; report severe or persistent symptoms.